Mora-Zúñiga A, Cárdenas-Arellano F, Cruz-Munguía J, Hernández-Carrillo J

Language: Spanish
References: 18
Page: 461-464
PDF size: 161.11 Kb.

ABSTRACT

Introduction: Chronic osteomyelitis is a disease usually of infectious origin. The main cause is post-traumatic, it affects the bone tissue and surrounding tissue, the most frequent causative agent is Staphylococcus aureus. The most affected bone is the tibia. Case description: A 42-year-old male with a diagnosis of chronic tibia osteomyelitis, with sequelae of previous surgical interventions, multiple antibiotic treatments, and type IV B classification by Cierny-Mader. Material and methods: Two-stage surgical management was chosen. Firstly, extensive bone and soft tissue debridement, placement of cement beads medicated with amikacin in the medullary cavity and osteoclast system for irrigation with vancomycin. In the second stage, free fibular bone grafting, fixation and stabilization with screws, bioactive glass placement in areas of interface between stabilized fibula and posterior tibial cortex. Results: Before a multitratada chronic osteomyelitis it is necessary to individualize and evaluate treatment alternatives, in this case the surgical management in two time, the use of medication beads, bone graft and the use of bioactive glass, achieved a complete eradication of the infection and favorable clinical evolution with optimal functional recovery of affected limb.

REFERENCES

1. Momodu II, Savaliya V. Osteomyelitis. 2022 Jan 24. In: StatPearls. Available in: https://www.ncbi.nlm.nih.gov/pubmed/30335283

2. Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011; 84(9): 1027-33.

3. Kusma J, Hombhanje F. Chronic osteomyelitis-bacterial flora, antibiotic sensitivity and treatment challenges. Open Ortho J. 2018; 12: 153-63.

4. Kinik H, Karaduman M. Cierny-Mader type III chronic osteomyelitis: the results of patients treated with debridement, irrigation, vancomycin beads and systemic antibiotics. Int Orthop. 2008; 32(4): 551-58.

5. García Del Pozo E, Collazos J, Cartón JA, Camporro D, Asensi V. Bacterial osteomyelitis: microbiological, clinical, therapeutic, and evolutive characteristics of 344 episodes. Rev Esp Quimioter. 2018; 31(3): 217-25.

6. Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ 3rd, Huddleston PM 3rd. Trends in the epidemiology of osteomyelitis a population-based study, 1969 to 2009. J Bone J Surg. 2015; 97(10): 837-45.

7. Ouedraogo S, Zida M, Tall M. Aspects épidémiologiques, bactériologiques et thérapeutiques des ostéomyélites chroniques en milieu subsaharien. Medecine et Sante Tropicales. 2017; 27: 292-5.

8. Nan J, Yun-Fei M, Xing-qi Z, Guo-ping X, Yan-Jun H, Cheng-he Q, et al. Clinical characteristics and treatment of extremity chronic osteomyelitis in southern China: A retrospective analysis of 394 consecutive patients. Medicine (Baltimore). 2015; 94(42): e1874.

9. Spellberg B, Lipsky B. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012; 54(3): 393-407.

10. Emara KM. Hemi-corticotomy in the management of chronic osteomyelitis of the tibia. Int Orthop. 2002; 26(5): 310-13.

11. Walter G, Jemmerer M, Kappler C, Hoffmann R. Treatment algorithms for chronic osteomyelitis. Dtsch Arztebl Int. 2012; 109(14): 257-64.

12. Yashavantha K, Nalini B, Jagdish M, Dilip K, Banerji B. Calcium sulfate as bone graft substitute in the treatment of osseous bone defects, a prospective study. J Clin Diagn Res. 2013; 7(12): 2926-8.

13. Oonishi H, Hench L, Wilson J, Sugihara F, Tsuji E, Matsuura M, et al. Quantitative comparison of bone growth behavior in granules of Bioglass, A-W glass-ceramic, and hydroxyapatite. J Biomed Mater Res. 2000; 51(1): 37-46.

14. Mckee M, Wild L, Schemitsch E, Waddell J. The use of an antibiotic-impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. J Orthop Trauma. 2002; 16(9): 622-7.

15. Calori G, Mazza E, Colombo M, Ripamoti C. The use of bone-graft substitutes in large bone defects: any specific needs? Injury. 2011; 42: S56-63.

16. Rizwan M, Hamdi M, Basirun W. Bioglass® 45S5 based composites for bone tissue engineering and functional applications. J Biomed Mater Res A. 2017; 105(11): 3197-223

17. Lindfors N, Geurts J, Drago L, Arts J, Juutilainen V, Huvonen P, et al. Antibacterial bioactive glass, S53P4, for chronic bone infections – A multinational study. Adv Exp Med Biol. 2017; 971: 81-92.

18. Romano C, Logoluso N, Meani E, Romano D, Vecchi E, Vassena, et al. A comparative study of the use of bioactive glass S53P4 abd antibiotic-loaded calcium-based bone substitutes in the treatment of chronic osteomyelitis. Bone Joint J. 2014; 96(B): 845-50.